{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VEGF&page=12",
    "query": {
      "intervention": "VEGF",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 829,
    "total_pages": 83,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VEGF&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VEGF&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T03:06:24.553Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02397954",
      "title": "A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Polypoidal Choroidal Vasculopathy"
      ],
      "interventions": [
        {
          "name": "Avacincaptad Pegol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ophthotech Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2015-03-12",
      "completion_date": "2015-10-23",
      "has_results": true,
      "last_update_posted_date": "2025-03-20",
      "last_synced_at": "2026-10-31T03:06:24.553Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02397954"
    },
    {
      "nct_id": "NCT04514653",
      "title": "RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration (nAMD)"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ABBV-RGX-314 Dose 1",
          "type": "GENETIC"
        },
        {
          "name": "ABBV-RGX-314 Dose 2",
          "type": "GENETIC"
        },
        {
          "name": "ABBV-RGX-314 Dose 3",
          "type": "GENETIC"
        },
        {
          "name": "Local Steroid",
          "type": "DRUG"
        },
        {
          "name": "Topical Steroid",
          "type": "DRUG"
        },
        {
          "name": "ABBV-RGX-314 Dose 4",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "50 Years to 89 Years"
      },
      "enrollment_count": 146,
      "start_date": "2020-08-25",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-10-31T03:06:24.553Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04514653"
    },
    {
      "nct_id": "NCT03585556",
      "title": "AAVCAGsCD59 for the Treatment of Wet AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Wet Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Intravitreal anti-VEGF",
          "type": "DRUG"
        },
        {
          "name": "Intravitreal AAVCAGsCD59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Oral prednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2018-09-13",
      "completion_date": "2022-01-18",
      "has_results": false,
      "last_update_posted_date": "2025-03-30",
      "last_synced_at": "2026-10-31T03:06:24.553Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Worcester, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03585556"
    },
    {
      "nct_id": "NCT00217737",
      "title": "Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Colon Adenocarcinoma",
        "Stage IIA Colon Cancer AJCC v7",
        "Stage IIB Colon Cancer AJCC v7",
        "Stage IIC Colon Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2431,
      "start_date": "2005-09-06",
      "completion_date": "2026-05-26",
      "has_results": true,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-10-31T03:06:24.553Z",
      "location_count": 910,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 578 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00217737"
    },
    {
      "nct_id": "NCT07392957",
      "title": "Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "CTX-009",
          "type": "DRUG"
        },
        {
          "name": "CTX-471",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2026-06-16",
      "completion_date": "2031-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-10-31T03:06:24.553Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07392957"
    },
    {
      "nct_id": "NCT00387751",
      "title": "Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Melanoma",
        "Stage III Skin Melanoma",
        "Stage IV Skin Melanoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Sorafenib Tosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 14,
      "start_date": "2006-08",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2017-11-22",
      "last_synced_at": "2026-10-31T03:06:24.553Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00387751"
    },
    {
      "nct_id": "NCT06662994",
      "title": "High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetic Macular Edema (DME)"
      ],
      "interventions": [
        {
          "name": "Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Retina Consultants of Orange County",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2025-07-07",
      "completion_date": "2027-08-15",
      "has_results": false,
      "last_update_posted_date": "2025-07-10",
      "last_synced_at": "2026-10-31T03:06:24.553Z",
      "location_count": 1,
      "location_summary": "Fullerton, California",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06662994"
    },
    {
      "nct_id": "NCT01232777",
      "title": "Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity (BLOCK-ROP)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Retinopathy of Prematurity"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vision Research Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Weeks",
        "maximum_age": "36 Weeks",
        "sex": "ALL",
        "summary": "30 Weeks to 36 Weeks"
      },
      "enrollment_count": 0,
      "start_date": "2012-06",
      "completion_date": "2018-07",
      "has_results": false,
      "last_update_posted_date": "2013-10-17",
      "last_synced_at": "2026-10-31T03:06:24.553Z",
      "location_count": 18,
      "location_summary": "Los Angeles, California • Palo Alto, California • Miami, Florida + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01232777"
    },
    {
      "nct_id": "NCT05802329",
      "title": "Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Center Involved Diabetic Macular Edema",
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "OCU200",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ocugen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2024-01-13",
      "completion_date": "2026-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-10-31T03:06:24.553Z",
      "location_count": 5,
      "location_summary": "Deerfield Beach, Florida • Erie, Pennsylvania • Bellaire, Texas + 2 more",
      "locations": [
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        },
        {
          "city": "Erie",
          "state": "Pennsylvania"
        },
        {
          "city": "Bellaire",
          "state": "Texas"
        },
        {
          "city": "Southlake",
          "state": "Texas"
        },
        {
          "city": "La Crosse",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05802329"
    },
    {
      "nct_id": "NCT00200200",
      "title": "Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatic Metastases",
        "Colon Cancer",
        "Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Bevacizumab HAI plus systemic chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "HAI plus systemic chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 73,
      "start_date": "2004-11-19",
      "completion_date": "2025-03-13",
      "has_results": true,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-10-31T03:06:24.553Z",
      "location_count": 5,
      "location_summary": "Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Uniondale",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00200200"
    }
  ]
}